Biotheus Inc.
Clinical trials sponsored by Biotheus Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Double-Action antibody takes on Hard-to-Treat neuroendocrine cancers Results expected Jan 2027 (estimated)
- New hope for tough lung cancer: Dual-Action drug combo in final testing Results expected Jan 2027 (estimated)
- Can a Two-Pronged antibody boost chemo against Hard-to-Treat colorectal cancer? Results expected May 2027 (estimated)
- Can an immunotherapy drug boost chemotherapy's power against a tough breast cancer? Results expected Jul 2027 (estimated)
-
Experimental drug combo aims to shrink inoperable liver tumors
Disease control CompletedThis phase II trial is testing whether a new biologic drug called PM8002, when combined with standard chemotherapy (FOLFOX), can shrink tumors in people with advanced liver cancer that cannot be removed by surgery. The study enrolls about 35 adults with inoperable hepatocellular …
Phase 2 • Sponsor: Biotheus Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New antibody-chemo combo shows promise for mesothelioma
Disease control CompletedThis study tested a new drug called PM8002, which targets two proteins that help cancer grow, combined with standard chemotherapy. It involved 31 adults with a rare cancer called malignant mesothelioma that could not be removed by surgery. The goal was to see if the combination s…
Phase 2 • Sponsor: Biotheus Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC